BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 176 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2020. The put-call ratio across all filers is 0.12 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $31,568,000 | -7.1% | 485,595 | +4.5% | 0.42% | +60.7% |
| Q2 2020 | $33,975,000 | -99.8% | 464,717 | -10.9% | 0.26% | +72.4% |
| Q1 2020 | $15,534,492,000 | -45.3% | 521,817 | 0.0% | 0.15% | -20.0% |
| Q4 2019 | $28,407,717,000 | +98524.2% | 521,817 | -24.4% | 0.19% | -5.5% |
| Q3 2019 | $28,804,000 | -4.7% | 690,417 | 0.0% | 0.20% | -3.4% |
| Q2 2019 | $30,233,000 | -14.9% | 690,417 | 0.0% | 0.21% | -17.1% |
| Q1 2019 | $35,535,000 | +39.2% | 690,417 | 0.0% | 0.25% | +16.2% |
| Q4 2018 | $25,532,000 | -1.5% | 690,417 | 0.0% | 0.22% | +16.1% |
| Q3 2018 | $25,925,000 | -5.0% | 690,417 | 0.0% | 0.19% | -13.5% |
| Q2 2018 | $27,285,000 | +61.1% | 690,417 | 0.0% | 0.22% | +62.9% |
| Q1 2018 | $16,935,000 | -9.1% | 690,417 | 0.0% | 0.13% | -33.3% |
| Q4 2017 | $18,627,000 | – | 690,417 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 896,844 | $123,594,000 | 67.92% |
| RP Management, LLC | 1,111,111 | $153,122,000 | 64.09% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,075,402 | $286,011,000 | 40.64% |
| ARS Investment Partners, LLC | 463,392 | $63,860,000 | 5.86% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 300,373 | $41,394,000 | 4.76% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 80,348 | $11,073,000 | 4.49% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 139,900 | $19,282,000 | 4.30% |
| Avidity Partners Management LP | 1,140,000 | $157,103,000 | 3.33% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 200,000 | $27,562,000 | 3.17% |
| Eventide Asset Management | 1,635,000 | $225,319,000 | 2.88% |